Olema Pharmaceuticals, Inc.
OLMA
$10.63
$0.121.14%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 81.19% | 45.47% | 18.38% | -1.12% | -6.74% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 50.30% | 34.33% | 22.91% | 16.21% | 23.19% |
| Operating Income | -50.30% | -34.33% | -22.91% | -16.21% | -23.19% |
| Income Before Tax | -43.76% | -43.65% | -25.47% | -22.24% | -29.80% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -43.76% | -43.65% | -25.47% | -22.24% | -29.80% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -43.76% | -43.65% | -25.47% | -22.24% | -29.80% |
| EBIT | -50.30% | -34.33% | -22.91% | -16.21% | -23.19% |
| EBITDA | -50.47% | -34.40% | -22.90% | -16.22% | -23.17% |
| EPS Basic | -6.91% | -0.81% | 15.66% | 14.56% | 4.00% |
| Normalized Basic EPS | -13.62% | 5.01% | 17.59% | 18.46% | 7.92% |
| EPS Diluted | -6.91% | -0.81% | 15.66% | 14.56% | 4.00% |
| Normalized Diluted EPS | -13.62% | 5.01% | 17.59% | 18.46% | 7.92% |
| Average Basic Shares Outstanding | 30.72% | 37.99% | 48.13% | 44.01% | 38.92% |
| Average Diluted Shares Outstanding | 30.72% | 37.99% | 48.13% | 44.01% | 38.92% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |